

OSTEOPORE ENTERS ORTHOPAEDIC MARKET WITH 2nd GENERATION PRODUCT REGISTERED IN GREAT BRITAIN

Highlights:

- *Osteopore's new line of product called aXOpore[®], has successfully been registered with the United Kingdom's Medicines & Healthcare products Regulatory Agency.*
- *Under the umbrella brand of aXOpore[®] are products made with Osteopore's 2nd generation bioresorbable material that exhibits structural and regeneration advantages for bone reconstruction applications.*
- *The registration enables aXOpore[®] to be used in Great Britain and can now be used by surgeons for treatment of their patients.*
- *Osteopore will now engage with hospitals and key surgeons, and will also seek potential distribution partners who have the network to support and scale the adoption of aXOpore[®] CMD in Great Britain.*

14 February 2023: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce its aXOpore[®] Custom-Made Device (CMD) has been registered with the Medicines and Healthcare products Regulatory Agency (MHRA). This will enable aXOpore[®] CMD access to Great Britain. Based on a commissioned market research, Osteopore now has access to approximately 3,000 cases of long bone malunion in Great Britain annually.

aXOpore[®] CMD is a customised implant used in long bone reconstruction surgery to replace bone loss as a result of trauma, surgery or pathological conditions. It is made from Polycaprolactone (PCL) and Tricalcium phosphate (TCP), a composite biomaterial that exhibits structural and regeneration advantages for bone reconstruction applications.

The registration enables aXOpore[®] CMD to be used in Great Britain, and can now be ordered and used by individual surgeons for treatment of their patients.

The registration comes at an opportune moment, with the British Limb Reconstruction Society (BLRS) meeting on the 23rd and 24th March in Belfast. The BLRS meeting presents an excellent platform for Osteopore to launch the aXOpore[®] CMD in Great Britain and share its clinical outcomes to a targeted audience. Osteopore will be at this meeting. In addition, two of Osteopore's key surgeons, who have championed the use of aXOpore[®] CMD to treat various long bone defects, will be presenting their insights and outcomes at this meeting.

Dr. Michael Wagels (Australia) is the first in the world to successfully reconstruct a 36cm shin bone using aXOpore[®] CMD in combination with his technique of Regenerative Matching Axial Vascularization. He has also performed several other “world’s firsts” by treating patients who suffered from large skull defects and jaw bone defects in a similar way, with excellent clinical success.

Dr. Sultan Al Maskari (Oman) has successfully treated patients with long bone defects over 20cm in length in combination, with his refined technique of combining the Masquelet technique and external fixation devices with aXOpore[®] CMD to achieve excellent post-operative outcomes.

Executive Chairman, Mark Leong said: *“This is a major milestone for us. Through the launch of aXOpore[®] CMD, Osteopore has now entered the orthopaedic market. In addition, this registration is a stepping stone towards expanding our scope of applications to cover the entire body. Our team will now seek out surgeons and partners to drive the adoption of aXOpore[®] CMD across Great Britain.”*

Chief Executive Officer, Goh Khoo Seng said: *“Entry into a new market brings about exciting opportunities for the business. I am glad that our team continues to work diligently to gain market access, and I am excited for the future.”*

Chief Operating and Chief Technology Officer, Dr Lim Jing said: *“We are very excited and encouraged to enter the orthopaedic market. This second generation technology has shown potential to transform patients’ lives, and we look forward to making our technology readily available to patients in Great Britain.”*

Further information about the BLRS

The BLRS was founded in 1997 with the objective of bringing together surgeons and allied health professionals involved in the management of congenital and acquired deformities of the upper and lower limbs, reconstruction of post traumatic limb defects and limb equalisation techniques.

The Society aims to advance education and research in the field of limb reconstruction and holds regular scientific meetings and training courses. The Society is affiliated with the British Orthopaedic Association and with the International ASAMI (Association for the Study and Application of the Method of Ilizarov).

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.